SCHEMBL22736727

SCHEMBL22736727

CCOC(=O)c1cn2c(n1)NCCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.41
GABRA2 P47869 4/20 0.40
GABRB2 P47870 4/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
TP53 P04637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RPS6KA3 P51812 1/20 0.39
SMO Q99835 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13734040 0.78 GAA (0.42) KDM4ENPC1RAB9ARXFP1ALDH1A1
SCHEMBL12443590 0.76 HPGD (0.60) KDM4ENPC1RAB9ARXFP1ALDH1A1
SCHEMBL13424113 0.75 HPGD (0.55) KDM4ENPC1RAB9ARXFP1ALDH1A1
SCHEMBL23534886 0.74 KDM4E (0.41) KDM4ENPC1RAB9ARXFP1ALDH1A1
SCHEMBL929672 0.74 PDCD1 (0.43) KDM4ENPC1RAB9ARXFP1ALDH1A1
SCHEMBL16281097 0.74 KDM4E (0.45) KDM4ENPC1RAB9ARXFP1ALDH1A1
SCHEMBL16281077 0.73 KDM4E (0.47) KDM4ENPC1RAB9ARXFP1ALDH1A1
SCHEMBL7183123 0.73 NPC1 (0.44) KDM4ENPC1RAB9ARXFP1ALDH1A1
Hydrochloric Acid SCHEMBL16741194 0.73 PDCD1 (0.43) KDM4ENPC1RAB9ARXFP1ALDH1A1
Hydrochloric Acid SCHEMBL2753179 0.73 PDCD1 (0.43) KDM4ENPC1RAB9ARXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200375987-A1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. (US) 2020-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200375987-A1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF SLC11A2, MMP12, LCT KDM4E 1897/4885NPC1 674/4885RAB9A 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.